Cell transplantation in liver-directed gene therapy

Area of Science:

• Biomedical research
• Gene therapy
• Hepatocyte transplantation

Background:

• Somatic cell gene therapy is an emerging therapeutic field.
• Hepatocyte transplantation is explored for genetic deficiencies.
• Two strategies exist: allogeneic and autologous cell transplantation.

Purpose of the Study:

• To review strategies for somatic cell gene therapy using hepatocyte transplantation.
• To evaluate allogeneic versus autologous hepatocyte transplantation.
• To highlight the potential of ex vivo gene therapy for inherited diseases.

Main Methods:

• Allogeneic hepatocyte transplantation: involves donor cells, requires immunosuppression, avoids recipient surgery.
• Autologous ex vivo gene therapy: involves harvesting patient hepatocytes, genetic correction using retroviruses, and re-transplantation.
• Animal models used include Gunn rats, Nagase analbuminemic rats, and Watanabe heritable hyperlipidemic rabbits.

Main Results:

• Allogeneic transplantation faces challenges of rejection and immunosuppression risks.
• Ex vivo gene therapy eliminates rejection and immunosuppression.
• Preclinical studies in Watanabe rabbits, dogs, and Papio spp. demonstrate safety and efficacy.

Conclusions:

• Ex vivo gene therapy using genetically corrected autologous hepatocytes is a promising approach for inherited diseases.
• Clinical trials are underway for familial hypercholesterolemia.
• Potential target diseases include familial hypercholesterolemia, ornithine transcarbamylase deficiency, and others.